Relevance of multidrug resistance to rheumatoid arthritis: Development of a new therapeutic hypothesis

Journal of Rheumatology

Volumn 23, Issue SUPPL. 44, 1996, Pages 97-101

  Salmon, Sydney E ^a,b,c   Dalton, William S ^a,b,c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b Department of Medicine ^*

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Antimalarials; Chemosensitizers; Cyclosporine; Multidrug resistance; Natural killer cells; P glycoprotein

Indexed keywords

ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; FLUOROURACIL; GLUCOCORTICOID; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; VERAPAMIL; GLYCOPROTEIN P;

ANIMAL EXPERIMENT; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; MULTIDRUG RESISTANCE; NATURAL KILLER CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; AUTOIMMUNITY; BIOLOGICAL MODEL; CHEMISTRY; DRUG ANTAGONISM; IMMUNOLOGY; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; DRUG RESISTANCE, MULTIPLE; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; P-GLYCOPROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029965251     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Pinedo HM, Longo DL, Chabner BA, eds. Cancer Chemotherapy and Biological Response Modifiers. Amsterdam, Elsevier, 1992.
2. Grogan T, Spier CM, Salmon SE, et al: P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy. Blood 1993;81:490-5.
3. Shulstik C, Dalton W, Gros P: P-glycoprotein-mediated multidrug resistance in tumor cells: Biochemistry, clinical relevance and modulation Molec Aspects Med 1995;16:1-78.
4. Bech-Hansen NT, Till JE, Ling V: Pleiotropic phenotype of colchicine-resistant CHO cells: cross resistance and collateral sensitivity. J Cell Physiol 1976;88:23-32.
5. Dalton WS, Grogan TM, Meltzer PS, et al: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989;7:415-24.
6. Salmon SE, Dalton WS, Grogan TM, et al: Multidrug-resistant myeloma, laboratory and clinical effects of verapamil as a chemosensitizer Blood 1991;78:44-50.
7. Sonneveld P, Dune BG, Lokhorst HM, et al: Modulation of multidrug-resistant multiple myeloma by cyclosporin A. The Leukaemia Group of the EORTC and the HOVON. Lancet 1992;340:255-9.
8. Miller TP, Grogan TM, Dalton WS, et al: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991; 9:17-24.
9. List AF, Spier C, Greer J, et al: Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993;11:1652-60.
10. Higgins CF: ABC transporters: From microorganisms to man. Annu Rev Cell Biol 1992;8 67-113.
11. Klimecki WT, Futscher BW, Grogan TM, Dalton WS: P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994;83:2451-8.
12. Klimecki WT, Taylor CW, Dalton WS: Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs. J Clin Immunol 1995;15:152-8.
13. Kagl D, Ledermann B, Burki K, et al: Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice Nature 1994;369:31-7.
14. Lowrey DM, Hameed A, Lichtenheld M, Podack ER. Isolation and characterization of cytotoxic granules from human lymphokine (interleukin 2) activated killer cells. Cancer Res 1988;48:4681-8.
15. Lichtenheld MG, Olsen KJ, Lu P, et al: Structure and function of human perform. Nature 1988;335:448-51.
16. Krahenbuhl O, Rey C, Jenne D, et al: Characterization of granzymes A and B isolated from granules of cloned human cytotoxic T lymphocytes. J Immunol 1988;141:3471-7
17. Tak PP, Kummer JA, Hack CE, et al: Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum 1994;37:1735-43.
18. Kummer JA, Tak PP, Brinkman BMN, et al: Expression of granzymes A and B in synovial tissue from patients with rheumatoid arthritis and osteoarthntis. Clin Immunol Immunopath 1994;73:88-95.
19. Arend WP, Dayer JM: Inhibition of the production and effects of interleukin-1 and Tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995,38:151-60.
20. Kuchler K, Thorner J: Secretion of peptides and proteins lacking hydrophobic signal sequences: The role of adenosine triphosphate-driven membrane translocators. Endocrin Rev 1992; 13:499-514.
21. Santiago-Schwarz F, Kay C, Panagiotopoulos C, Carsons SE: Rheumatoid arthritis serum or synovial fluid and interleukin 2 abnormally expand natural killer-like cells that are potent stimulators of IgM rheumatoid factor. J Rheumatol 1992,19:223-8.
22. Reem GH, Gook LA, Vilcek J: Gamma interferon by human thymocytes and T lymphocytes inhibited by cyclosporine A. Science 1983;221:63-5.
23. Kronke M, Leonard WJ, Depper JM, et al: Cyclosporine A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA 1954;82;5214-8.
24. McCaffrey PG, Goldfeld AE, Rao A: The role of NFATp in cyclosporin A-sensitive tumor necrosis factor-alpha gene transcription. J Biol Chem 1994;269:30445-50.
25. Kirwan JR, the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group: The effect of glucocorticoids on joint destruction in rheumatoid arthritis N Engl J Med 1995;333:142-6.
26. Bourgeoi S, Gruol DJ, Newby BRF, Rajah FM: Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol 1993;7:840-51.
27. Tugwell P, Pincus T, Yocum D, et al: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
28. Cole SP, Bhardwaj G, Gerlach JH, et al: Overexpression of a transporter gene in a multidrug-resistant human cancer cell line. Science 1992;258:1650-4.
29. Scheffer GL, Wijngaard PLJ, Flens MJ, et al: The drug resistance related protein LRP is a major vault protein. Nature Med 1995;1:578-82.
30. Ruetz S, Gros P: Phosphatidylcholine translocase: A physiological role for the mdrα gene. Cell 1994;77:1071-81.